2010
The Advantage of using PET SUV to Evaluate Tumor Response by RECIST Criteria in Patients with Stage IIIA/B Non-small Cell Lung Cancer (NSCLC) after Concurrent Chemotherapy and Tarceva with Radiotherapy
Wei X, Allen P, Blumenschein G, Hong W, Herbst R, O'Reily M, Heymach J, Erasmus J, Lee J, Komaki R. The Advantage of using PET SUV to Evaluate Tumor Response by RECIST Criteria in Patients with Stage IIIA/B Non-small Cell Lung Cancer (NSCLC) after Concurrent Chemotherapy and Tarceva with Radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2010, 78: s498. DOI: 10.1016/j.ijrobp.2010.07.1165.Peer-Reviewed Original Research
2007
First-in-human study of AMG 386, a selective angiopoietin1/2-neutralizing peptibody, in adult patients with advanced solid tumors
Rosen L, Hong D, Chap L, Kurzrock R, Garcia A, Rasmussen E, Nguyen L, Hwang Y, Storgard C, Herbst R. First-in-human study of AMG 386, a selective angiopoietin1/2-neutralizing peptibody, in adult patients with advanced solid tumors. Journal Of Clinical Oncology 2007, 25: 3522-3522. DOI: 10.1200/jco.2007.25.18_suppl.3522.Peer-Reviewed Original ResearchAMG 386Advanced solid tumorsAdverse eventsStable diseaseTumor responseHuman studiesGrade 2Solid tumorsDCE-MRIMinor clinical responseSignificant vascular effectsSerum CA 125Treatment-related toxicityDose-limiting toxicityFurther clinical studiesEvaluable patientsEvaluable subjectsPeripheral edemaRECIST criteriaAdult patientsClinical responseProgressive diseaseWeekly administrationVascular effectsCA 125